@article {L {\ ' o} pez-Menae1933作者={迭戈L {\ ' o} pez-Mena和米格尔Garc{\ \我}a-Grimshaw和塞尔吉奥Saldivar-D{\ '}维拉和劳拉Elena Hernandez-Vanegas和Mar{\ \我}德尔Saniger-Alba和阿隆索古蒂{\ ' e} rrez-Romero赫克托耳和罗杰Carrillo-Mezo爱德华多Valdez-Ruvalcaba瓦妮莎Cano-Nigenda和费尔南多·丹尼尔Flores-Silva卡洛斯斜面{\ ' u}布里托,安娜Mar{\ \我}Santiba {\ ~ n} ez-Copado和jose Luis Diaz-Ortega圣伊丽莎白Ceballos-Liceaga和路易斯·曼纽尔Murillo-Bonilla安娜伊莎贝尔Sepulveda-N {\ ' u} {\ ~ n} ez和版本{\ ' o} nica Garc{\ \我}a-Talavera爱德华多Gonzalez-Guerra和里卡多Cortes-Alcala雨果Lopez-Gatell和Guillermo Carbajal-Sandoval Gustavo Reyes-Ter {\ ' n}和塞尔吉奥Iv {\ ' n} Vald {\ ' e} s-Ferrer和安东尼奥Arauz}, title ={中风在墨西哥SARS-CoV-2疫苗接受者},体积={98}={19},页面= {e1933——e1941} = {2022}, doi = {10.1212 / WNL。出版商0000000000200388}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={背景和目标信息中风在严重急性呼吸系统综合症冠状病毒2 (SARS-CoV-2)首页疫苗仍然稀缺。我们报告中风发病率作为免疫接种后不良事件(AEFI)在接受79399446剂量的6种SARS-CoV-2疫苗(BNT162b2, ChAdOx1 nCov-19, Gam-COVID-Vac, CoronaVac, Ad5-nCoV,和Ad26.COV2-S)在12月24日,2020年8月31日,2021年,在墨西哥。方法回顾性描述性研究分析中风发病率每百万剂量住院成人患者(> = 18年)在为期8个月的时间间隔。根据世界卫生组织,免疫接种后不良事件被定义为临床事件发生后30天内免疫和归类为不严重或严重,根据严重程度,治疗和住院的需求。颅内出血急性缺血性中风(AIS),(我),蛛网膜下腔出血(SAH)和脑静脉血栓形成(CVT)情况下通过一个被动的流行病学监测系统收集的当地卫生提供者报告潜在的AEFI墨西哥一般流行病学委员会。数据捕获与标准化的病例报告格式由一个特别委员会任命的墨西哥卫生部对SARS-COV-2评估潜在的神经免疫接种后不良事件。结果包括56例(31岁女性病人[55.5 \ %])的总发病率每1000000人0.71例服用剂量(95 \ % CI 0.54 {\ textendash} 0.92)。平均年龄是65岁(四分位距(差)55 {\ textendash} 76年);中位数时间从接种到中风(任何子类型)2天(差1 {\ textendash} 5天)。在27个(48.2 \ %)患者中,事件后第一个24小时内被诊断免疫。最常见的亚型在43例AIS (75 \ %;0.54每1000000剂量,CI 95 \ % 0.40 0.73 {\ textendash}),其次是我在9 (16.1 \ %; 0.11 per 1,000,000 doses, 95\% CI 0.06{\textendash}0.22) and SAH and CVT, each with 2 cases (3.6\%; 0.03 per 1,000,000 doses, 95\% CI 0.01{\textendash}0.09). Overall, the most common risk factors were hypertension in 33 (58.9\%) patients and diabetes in 22 (39.3\%). Median hospital length of stay was 6 days (IQR 4{\textendash}13 days). At discharge, functional outcome was good (modified Rankin Scale score 0{\textendash}2) in 41.1\% of patients; in-hospital mortality rate was 21.4\%.Discussion Stroke is an exceedingly rare AEFI against SARS-CoV-2. Preexisting stroke risk factors were identified in most patients. Further research is needed to evaluate causal associations between SARS-COV-2 vaccines and stroke.AEFI=adverse event following immunization; AIS=acute ischemic stroke; CVD=cardiovascular disease; CVT=cerebral venous thrombosis; ICH=intracerebral hemorrhage; IQR=interquartile range; mRS=modified Rankin Scale; SAH=subarachnoid hemorrhage; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2; TOAST=Trial of ORG 10172 in Acute Stroke Treatment; VITT=vaccine-induced immune thrombotic thrombocytopenia; WHO=World Health Organization}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/98/19/e1933}, eprint = {//www.ez-admanager.com/content/98/19/e1933.full.pdf}, journal = {Neurology} }